Thioridazine

also known as Mellaril · TDZ

targets DRD2 via inhibition

Developed for: schizophrenia · acute myeloid leukemia · schizoaffective disorder
Investigated by: Hamilton Health Sciences Corporation · Hannover Medical School · Juravinski Cancer Centre Foundation · New Mexico Cancer Research Alliance · Ontario Clinical Oncology Group (OCOG) · Oxnard Foundation
+1 more
· Technical University of Munich

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	MELLARIL	—	2007-12-07	fda.gov ↗
Approved	US (FDA)	MELLARIL	—	1962-03-15	fda.gov ↗

Trials 4

today

US approved 1962

NCT02307396 · Ph 4 NCT02374567 · Ph 3 NCT02096289 · Ph 1 NCT01765803 · Ph 0

19611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT01765803	Jun → Nov 2013	—	New Mexico Cancer Research Alliance	Terminated	No outcome recorded
Phase 11 trial
Phase 1	NCT02096289	Jul 2014 → Aug 2016	acute myeloid leukemia	Ontario Clinical Oncology Group (OCOG)	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 41 trial
Phase 4	NCT02307396	Feb 2015 → Jun 2016	schizoaffective disorder, schizophrenia	Technical University of Munich	Completed	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	Thioridazine	“This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow...” NCT01765803 ↗ 3 NCT02307396 ↗ NCT02096289 ↗ NCT02374567 ↗
Known as	Mellaril	“This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow...” NCT01765803 ↗
Known as	TDZ	“We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine.” PMID 30093531 ↗ Aug 2018
Action	Inhibit	“We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine.” PMID 30093531 ↗ Aug 2018
Route	Oral	“will be given orally” NCT01765803 ↗
Target	DRD2	“The extent of blast reduction during this 5-day interval was associated with the expression of the putative TDZ target receptor DRD2 on leukemic cells.” PMID 30093531 ↗ Aug 2018